Abstract: The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

Abstract: The present invention relates generally to a novel human T-cell lymphotropic, or leukemia, virus type II (HTLV-II) isolate designated NRA. HTLV-IINRA was originally isolated from a patient with atypical hairy cell leukemia. Preliminary restriction analysis of this isolate demonstrated that it differs genetically from the prototypical HTLV-II isolate Mo. HTLV-IINRA proviral molecular clones were obtained and the entire nucleotide sequence of the virus ascertained. The claimed invention is particularly directed toward the gp46 and p21e envelope proteins encoded by the env gene. Methods and kits for the detection of HTLV-II antibodies employing these envelope proteins are also described.

Abstract: The present invention provides a method of synthesizing genes encoding unique HIV-1 and HIV-2 envelope proteins and their fragments, thereby allowing overexpression of these proteins in E. coli. The HIV envelope proteins and their fragments have been expressed at high levels as individual proteins or in fusion with other proteins. The HIV envelope proteins thus expressed in E. coli can be effectively used for the detection of exposure to HIV as well as the discrimination of HIV-1 and HIV-2.

Abstract: Binary pharmaceutical compositions comprising (i) a cyclosporine compound, (ii) a hydrophilic phase and (iii) a surfactant provide bioavailability of the active ingredient which is equivalent to that provided by ternary compositions, but without the need for a lipophilic phase.

Abstract: A method of performing a rapid assay for the simultaneous detection and differentiation of the analytes HIV-1 group M. HIV-1 group O and HIV-2 utilizing a sequence specific polypeptide of each analyte as capture reagents. An analytical. device also is provided for performing the method which includes these capture reagents. Also provided is a test kit which includes the analytical device which further can include a positive and negative control.

Abstract: Analogs of human erythropoietin, including the ?X.sup.33, Cys.sup.139, des-Arg.sup.166 ! and ?Cys.sup.139, des-Arg.sup.166 ! analogs, as well as methods for making and using such analogs and pharmaceutical compositions containing the same.

Abstract: This invention relates to genetically engineered enzymes, their ligand conjugates, their manufacture, and their use in qualitative or quantitative assays. A hybrid enzyme, such as an AP-epitope, has a foreign amino acid moiety (an epitope) inserted near the active site of the starting AP enzyme. The foreign amino acid moiety binds with an analyte, and, as a consequence of this binding, the enzymatic activity of the hybrid enzyme, AP-epitope, is modified. The changes in the enzymatic activity are dependent upon the presence, or the amount, of the analyte. In another embodiment, the hybrid enzyme consists of a cysteine introduced near the active site of an AP to give a hybrid enzyme. The cysteine on the hybrid enzyme serves as a point of conjugation of a ligand, such as theophylline, ferritin, thyroxine, or digoxigenin, to form the hybrid enzyme-ligand conjugate.

Abstract: A method to produce novel polyketide structures by designing and introducing specified changes in the DNA governing the synthesis of the polyketide is disclosed. The biosynthesis of specific polyketide analogs is accomplished by genetic manipulation of a polyketide-producing microorganism by isolating a polyketide biosynthetic gene-containing DNA sequence, identifying enzymatic activities associated within the DNA sequence, introducing one or more specified changes into the DNA sequence which codes for one of the enzymatic activities which results in an altered DNA sequence, introducing the altered DNA sequence into the polyketide-producing microorganism to replace the original sequence, growing a culture of the altered microorganism under conditions suitable for the formation of the specific polyketide analog, and isolating the specific polyketide analog from the culture.

Abstract: A process for producing high purity 6,12-dideoxyerythromycin A using recombinant DNA technology is disclosed. The erythromycin producing strain, Saccharopolyspora erythraea, lacking the erythromycin C-12 and C-6 hydroxylases produces a mixture of 6,12-dideoxyerythromycin A and the precursor molecule, 6-deoxyerythromycin D. To achieve conversion of the precursor to the final product, a second copy of eryG is inserted into a non-essential region of the Sac. erythraea chromosome resulting in high purity 6,12-dideoxyerythromycin A.

Abstract: HIV-1 peptides having at least one point mutation between position 593 and 611 of the HIV-1 gp160 amino acid sequence. The point mutation either is at position 604 or 610, or both positions. Immunoassays which utilize these peptides are provided, as well as, diagnostic test kits which contain these peptides.

Abstract: Novel bacterial isolates of B. thuringiensis are disclosed which have enhanced toxicity with respect to previously resistant or insufficiently susceptible insect species, including, but not limited to, Plutella xylostella, Spodoptera frugiperda and Spodoptera exigua, as well as certain secondary pests such as Trichoplusia ni. Such isolates may be characterized by their possession of a particular subset of the genes coding for the various B. thuringiensis .delta.-endotoxin proteins and by a characteristic plasmid profile, or array, known to be associated therewith.

Abstract: A process for producing high purity 6,12-dideoxyerythromycin A using recombinant DNA technology is disclosed. The erythromycin producing strain, Saccharopolyspora erythraea, lacking the erythromycin C-12 and C-6 hydroxylases produces a mixture of 6,12-dideoxyerythromycin A and the precursor molecule, 6-deoxyerythromycin D. To achieve conversion of the precursor to the final product, a second copy of eryG is inserted into a non-essential region of the Sac. erythraea chromosome resulting in high purity 6,12-dideoxyerythromycin A.

Abstract: Methods of differentiation of sera containing antibodies to HTLV-I from sera containing antibodies to HTLV-II are provided, along with peptides for their differentiation. Articles of manufacture containing these peptides are provided which allow for the differentiation of HTLV-I from HTLV-II infected sera.

Abstract: An assay and test kit of the determination of LKM-1 autoantibodies in test samples suspected of containing anti-LKM-1 autoantibodies. The method uses a solid phase which preferably is a microparticle. The method is standardized and can be performed in automated systems, allowing quantitation of the amount of anti-LKM antibody in test samples.

Abstract: Proteins heterologous to B. megaterium can be expressed in B. megaterium using a sporulation promoter from B. subtilis.

Abstract: A novel process for recovering water insoluble compounds from a fermentation broth includes sequential steps of concentrating, solubilizing and diafiltering the compound of interest, all through a single closed recirculation system to recover the compound for further downstream purification.

Abstract: A process for the manufacture of vancomycin which does not require preparation of a phosphate intermediate. The process consists of passing a vancomycin broth through a suitable adsorbent, followed by passing the vancomycin through a second adsorbent, producing a purified vancomycin. Purified vancomycin is then crystallized from the solution by adding a base solution that imparts a pH of above about 9.0 to about 9.5 to the purified vancomycin. The crystallized vancomycin is separated from the solution, dissolved in solution and recrystallized by adding a base solution which imparts a pH of above about 9.0 to about 9.5 to the dissolved solution. The recrystallized vancomycin is dissolved and titrated with hydrochloric acid. Vancomycin. HCl is then precipitated from the solution using an organic solvent.

Abstract: Immunomodulatory macrocyclic compounds having the formula: ##STR1## and pharmaceutically-acceptable salts, esters, amides and prodrugs thereof, as well as pharmaceutical compositions containing the same, which possess immunosuppressive, antimicrobial, antifungal, antiviral, antiinflammatory and antiproliferative activity, as well as the ability to reverse chemotherapeutic drug resistance.

Abstract: A method for the separation of gibberellins from mixtures thereof by selective silylation or desilylation, as well as substantially pure gibberellins prepared thereby.

Abstract: Immunomodulatory macrocyclic compounds having the formula: ##STR1## and pharmaceutically acceptable salts, esters, amides and prodrugs thereof,where R.sup.8 and R.sup.9 are selected such that one of R.sup.8 and R.sup.9 is hydrogen and the other is --S(O).sub.s --heterocyclic,as well as pharmaceutical compositions containing such compounds and therapeutic methods of their use.